Will 14-3-3η Be a New Diagnostic and Prognostic Biomarker in Rheumatoid Arthritis? A Prospective Study of Its Utility in Early Diagnosis and Response to Treatment

Table 1

A comparison of the sensitivity of various RA biomarkers in patients with early and established disease. Serum 14-3-3 levels (ng/ml) were compared between the two RA groups, as well as the control and comparison of serum 14-3-3 levels before and after anti-TNF therapy in group I patients.

	Group I (early RA) (n = 80)	Group II (established RA) (n = 80)	χ^2:
RF	61.7%	78.3%	3.968	0.0464
ACCP	68.3%	85%	4.658	0.0309
14-3-3η	86.7%	88.3%	0.0762	0.0783
χ^2:	17.023 < 0.001	3.854 0.146
Serum 14-3-3η levels (ng/ml)	Group I (early RA) (n = 80)	Control	t
Min.-Max.	0.15–4.3	0.00–1.26	25.45	<0.001
Mean ± SD	2.34 ± 0.42	0.13 ± 0.56
Serum 14-3-3η levels	Group II (established RA) (n = 80)	Control	t
Min.-Max.	0.17–5.1	0.00–1.26	37.88	<0.001
Mean ± SD	3.15 ± 0.26	0.13 ± 0.56
Serum 14-3-3η in group I	Mean ± SD	T
Before treatment	2.34 ± 0.42	2.952		0.004
After treatment	2.03 ± 0.63

MC: Monte Carlo; χ²: chi-square test.